Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.41 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.41 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248784 | 0.81 | TSHR (0.44) | CYP1A2GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5731977 | 0.77 | GPR35 (0.38) | GPR35CYP1A2GRIA1GRIA2GRIA3 | |
| SCHEMBL8596930 | 0.77 | L3MBTL1 (0.48) | CYP1A2GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2149064 | 0.75 | GPR35 (0.38) | GPR35CYP1A2BLMLMNAHPGD | |
| SCHEMBL9954720 | 0.74 | GPR35 (0.40) | GPR35CYP1A2GRIA1GRIA2GRIA3 | |
| SCHEMBL31107905 | 0.74 | ALDH1A1 (0.44) | CYP1A2GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL16362079 | 0.74 | NOS1 (0.42) | CYP1A2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30445055 | 0.74 | NOS1 (0.42) | CYP1A2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2149156 | 0.73 | OGT (0.43) | GPR35CYP1A2GRIA1GRIA2GRIA3 | |
| SCHEMBL30444318 | 0.73 | KMO (0.35) | CYP1A2BLMLMNATSHRKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3283077-A2 | BROMODOMAIN INHIBITOR | Celgene Quanticel Research, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | GPR35 4057/4885CYP1A2 4780/4885GRIA1 1881/4885 |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | GPR35 4047/4885CYP1A2 4776/4885GRIA1 1831/4885 |
| US-10807982-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | GPR35 4057/4885CYP1A2 4780/4885GRIA1 1881/4885 |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | GPR35 4057/4885CYP1A2 4780/4885GRIA1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.